ACTRN12612000010897
Completed
Phase 4
A randomised, double blind trial of Azithromycin versus Amoxycillin-Clavulate to treat mild to moderate respiratory exacerbations in children with non-Cystic Fibrosis bronchiectasis, Study Two.
Qld Children's Medical Research Institute0 sites170 target enrollmentJanuary 4, 2012
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Bronchiectasis
- Sponsor
- Qld Children's Medical Research Institute
- Enrollment
- 170
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged less than 18 years.
- •Bronchiectasis, as defined by HRCT scan within the last 5\-years OR followed by a respiratory physician for treatment of bronchiectasis if diagnosed earlier.
- •2 or more respiratory exacerbations of bronchiectasis symptoms in the last 18 months prior to study enrolment.
Exclusion Criteria
- •Cystic Fibrosis (sweat chloride \>35mmol/L or gene mutation). Liver dysfunction. Severe (hypoxic, dyspnoea or hospitalisation required) or recent exacerbation (in the last 4 weeks prior to study enrollment. Known hypersensitivity to macrolides or penicillins. Taking regular maintenance antibiotics of the same class as the investigational antibiotics (macrolides and penicillins), or has taken macrolides or penicillins within 3 weeks of study enrolment. Current or recent (within 4 months prior to study enrolment) identification of pseudomonas organism in the airways. Current treatment for an oncology condition of any kind.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A comparison of azithromycin and ofloxacin in the treatment of typhoid in adult patients in LaosTyphoid feverInfections and InfestationsISRCTN66534807niversity of Oxford (UK)88
Active, not recruiting
Not Applicable
An open-label, multi-center trial of azithromycin pharmacokinetics in sinus aspirate and serum following oral administration of either a 500 mg immediate-release (IR) once-daily 3 day regimen or a single-dose 2.0g azithromycin microspheres regimen in subjects with acute bacterial sinusitis.Acute bacterial sinusitisMedDRA version: 7.1Level: LLTClassification code 10060841EUCTR2005-000639-13-SEPfizer Ltd30
Completed
Not Applicable
Antibiotics to prevent preterm birthISRCTN84023116niversity of Liverpool (UK)2,300
Unknown
Phase 4
Azithromycin in Hospitalized COVID-19 PatientsCOVID-19NCT04359316Shahid Beheshti University of Medical Sciences40
Completed
Not Applicable
Prospective observational study of azithromycin in patients with acute exacerbation of fibrosing interstitial pneumoniaacute exacerbation of fibrosing interstitial pneumoniaJPRN-jRCT1090220095Dividion of respiratory medicine, Saiseikai Kumamoto Hospital30